ライフサイエンスコーパス: liver transplant recipient

1 tential interaction of the microbiome in the liver transplant recipient.

2 the leading cause of mortality in kidney and liver transplant recipients.

3 verall costs compared to prophylaxis in D+R- liver transplant recipients.

4 uracy for the diagnosis of IFIs in high-risk liver transplant recipients.

5 ed with increased morbidity and mortality in liver transplant recipients.

6 to isoniazid for tuberculosis prophylaxis in liver transplant recipients.

7 A cross-sectional study was conducted in 244 liver transplant recipients.

8 treatment of CMV disease, particularly among liver transplant recipients.

9 ated with allograft dysfunction in pediatric liver transplant recipients.

10 ts seem to play a key role in non-alcoholic, liver transplant recipients.

11 adherence to immunosuppression in pediatric liver transplant recipients.

12 aring regimens for antifungal prophylaxis in liver transplant recipients.

13 g echinocandins as antifungal prophylaxis in liver transplant recipients.

14 e part of the standard of care for pediatric liver transplant recipients.

15 ic method for GI tract disease in kidney and liver transplant recipients.

16 icity for CMV GI tract disease in kidney and liver transplant recipients.

17 ors is only possible in approximately 20% of liver transplant recipients.

18 rosis especially following HCV recurrence in liver transplant recipients.

19 review three cases of AMR in ABO-compatible liver transplant recipients.

20 its negative impact on long-term survival in liver transplant recipients.

21 ive observational study was conducted in 102 liver transplant recipients.

22 apid fibrosis progression observed in HCV(+) liver transplant recipients.

23 in a longitudinal study of 41 kidney and 33 liver transplant recipients.

24 was performed on whole blood samples of 548 liver transplant recipients.

25 the development of chronic kidney disease in liver transplant recipients.

26 providers, patients with liver disease, and liver transplant recipients.

27 of donor and recipient IL28B genotypes among liver transplant recipients.

28 ported to increase risk of graft failure for liver transplant recipients.

29 d function in the initial recovery period in liver transplant recipients.

30 in healthy, CMV-positive individuals and in liver transplant recipients.

31 and posttransplant hospitalization rates for liver transplant recipients.

32 and early allograft failure in HCV-positive liver transplant recipients.

33 MELD scores and waiting times of liver transplant recipients.

34 lovir prophylaxis for CMV prevention in D+R- liver transplant recipients.

35 ociated with severe recurrent HCV disease in liver transplant recipients.

36 h-degree ACR are decreased in living-related liver transplant recipients.

37 levels with postreperfusion damage in human liver transplant recipients.

38 invasive aspergillosis was evaluated in 154 liver transplant recipients.

39 ipients but did not occur in any of the four liver transplant recipients.

40 poor outcome in hepatitis C virus-coinfected liver transplant recipients.

41 enced 14 episodes of hepatic abscess, all in liver transplant recipients.

42 ophylaxis of CMV disease in CMV-seropositive liver transplant recipients.

43 %) prevailed as digestive tract pathogens in liver transplant recipients.

44 ving trends in invasive fungal infections in liver transplant recipients.

45 donor liver pool available for select adult liver transplant recipients.

46 split-liver transplantation in select adult liver transplant recipients.

47 roscopic approach has never been reported in liver transplant recipients.

48 (CKD) jeopardizes the long-term outcomes of liver transplant recipients.

49 mine is a nonnephrotoxic imaging modality in liver transplant recipients.

50 prevalent cause of non-hepatic mortality in liver transplant recipients.

51 etermined if this is equally detrimental for liver transplant recipients.

52 the treatment of metabolic comorbidities in liver transplant recipients.

53 ommon aim of improving care and outcomes for liver transplant recipients.

54 This retrospective study included 282 HCC liver transplant recipients.

55 lant indication and the ageing population of liver transplant recipients.

56 PET or prophylaxis for 100 days in 205 D+R- liver transplant recipients.

57 opment of BCs in a large cohort of pediatric liver transplant recipients.

58 crolimus (Advagraf) initiation in kidney and liver transplant recipients.

59 ipients, and as digestive tract pathogens in liver transplant recipients.

60 nown whether a similar association exists in liver transplant recipients.

61 ransplant recipients and 10%, 9%, and 13% in liver transplant recipients.

62 t-limiting toxic effects in immunosuppressed liver-transplant recipients.

63 were assessed in a cohort of 216 consecutive liver-transplant recipients.

64 outcomes of 7 renal transplant recipients, 1 liver transplant recipient, 1 heart transplant recipient

65 ients (715 kidney transplant recipients, 190 liver transplant recipients, 102 lung transplant recipie

66 ctively evaluated among pediatric kidney and liver transplant recipients, 12 months posttransplantati

67 PCR results were available for 81 kidney and liver transplant recipients; 20 cases of confirmed CMV G

68 nsplant (37 kidney-transplant recipients, 10 liver-transplant recipients, 5 heart-transplant recipien

69 We included 33,668 HCV+ liver transplant recipients (54.0 +/- 7.7 years old, 74.

70 Of the 326 included liver transplant recipients, 70 patients (21.5%) reached

71 y, among clinically and biochemically stable liver transplant recipients, a subset with histological

72 nd AT1R antibodies in 2 cohorts of pediatric liver transplant recipients: a stable control cohort wit

73 cryptococcosis was significantly higher for liver transplant recipients (adjusted hazard ratio [HR],

74 tive PTLD in an 18-month-old small bowel and liver transplant recipient after one infusion of partial

75 fied a population-based cohort of first-time liver transplant recipients (aged >=16 years) between 20

76 In 70 patients, 36 liver transplant recipients (ages 2-23 years) and 34 hea

77 sted dose in combination with Tac in de novo liver transplant recipients allows CS discontinuation fr

78 ed patient and graft survival rates in adult liver transplant recipients, analyzing outcomes based on

79 h only one case of TMAT, which occurred in a liver transplant recipient and resulted in death from bl

80 ctional, multicenter study that included 344 liver transplant recipients and examined the level of gl

81 vestigated plasma CD154 levels in kidney and liver transplant recipients and found no evidence that C

82 g early have been observed, especially among liver transplant recipients and in cases of graft-transm

83 tial immune suppressive potency in renal and liver transplant recipients and may be safely dosed for

84 immunoregulatory proteogenomic signatures in liver transplant recipients and may therefore facilitate

85 of blood specimens from pediatric and adult liver transplant recipients and normal tissues.

86 infections has been documented previously in liver transplant recipients and patients with cirrhosis.

87 llular carcinoma incidence is elevated among liver transplant recipients and subsets of non-liver rec

88 nd actinic keratoses in high-risk kidney and liver transplant recipients and to assess associated fac

89 T399I SNPs were assessed in a cohort of 706 liver transplant recipients and were associated with the

90 at the A locus decreases patient survival in liver transplant recipients, and mismatching at the DR a

91 cipients and as digestive tract pathogens in liver transplant recipients, and Pseudomonas aeruginosa

92 ts does not differ from that of HIV-negative liver transplant recipients, and they suggest that HIV i

93 splant portal vein thrombosis in a cohort of liver transplant recipients, and to identify independent

94 ver transplantation and the implications for liver transplant recipients are not well understood and

95 t of metabolic comorbidities specifically in liver transplant recipients are scarce, there is detaile

96 Pediatric liver transplant recipients arguably have the most to ga

97 ver biopsy specimens obtained from 15 HCV(+) liver transplant recipients at 6 and/or 12 months posttr

98 MRI with low-dose gadobenate dimeglumine in liver transplant recipients at a single center.

99 ective review in a large cohort of pediatric liver transplant recipients at a single institution to d

100 ot adequate for prevention of CMV disease in liver transplant recipients at high risk for CMV disease

101 e rate of CMV infection were assessed in 232 liver transplant recipients at our institution during a

102 ed over the last 10 years in 190 consecutive liver transplant recipients at our institution.

103 ble-blind trial of antifungal prophylaxis in liver transplant recipients at risk for invasive fungal

104 xpression in liver tissue and serum of adult liver transplant recipients before, early, and late afte

105 l, data were collected from 1799 consecutive liver transplant recipients between January 1, 2002, and

106 The postoperative clinical course of 212 liver transplant recipients between January 2008 and Apr

107 Kidney and liver transplant recipients between May 2014 and August

108 surgical technique and medical management of liver transplant recipients, biliary complications remai

109 portal blood samples obtained from 67 human liver transplant recipients both pre- [portal vein (PV)

110 nd graft survival between obese and nonobese liver transplant recipients, but obesity presents import

111 cause significant morbidity and mortality in liver transplant recipients, but the need and best agent

112 Liver transplant recipients can be converted from twice-

113 Our data is encouraging and shows that if liver transplant recipients can tolerate treatment for 1

114 ity would significantly advance personalized liver transplant recipient care and management of immuno

115 Perioperative renal dysfunction in liver transplant recipients complicates maintenance immu

116 Assigning a morphometric age to potential liver transplant recipients could improve prediction of

117 We aggregated national liver transplant recipient data between 2005 and 2009 to

118 The MELD scores and waiting time of liver transplant recipients differed by transplantation

119 score at transplantation and waiting time of liver transplant recipients differs by transplantation c

120 ndings suggest that survival of HIV-positive liver transplant recipients does not differ from that of

121 lood and liver tissue samples collected from liver transplant recipients enrolled in a prospective mu

122 iRNA) profiling in 318 serum samples from 69 liver transplant recipients enrolled in the Immune Toler

123 Liver transplant recipients experienced a significant 70

124 roborated by sequence analyses of HCV from a liver transplant recipient experiencing viral breakthrou

125 d Transplantation Network database of 52,435 liver transplant recipients from 1995 through 2005.

126 y of Transplant Recipients for primary adult liver transplant recipients from 2001 to 2009.

127 ents database was reviewed to identify adult liver transplant recipients from 2002 through 2016 with

128 followed serum DSA levels of 90 consecutive liver transplant recipients from baseline to 4 months.

129 d graft survival was significantly worse for liver transplant recipients from donors with ITP compare

130 ecipients from donors with ITP compared with liver transplant recipients from donors without ITP (64%

131 dialysis data, we assembled a cohort of 4997 liver transplant recipients from February 27, 2002-Janua

132 ewed the clinical charts of kidney or kidney/liver transplant recipients from January 2005 to Decembe

133 Among young first isolated liver transplant recipients, graft failure risks are hig

134 In 1997-2002, 4.6% of liver transplant recipients had HCC compared with 26% in

135 , previous analysis of human bone marrow and liver transplant recipients has demonstrated that platel

136 The prevalence of alcohol use among Finnish liver transplant recipients has not been studied before.

137 lae associated with cytomegalovirus (CMV) in liver-transplant recipients has not been clearly delinea

138 Liver transplant recipients have a high prevalence of ri

139 se that occurs despite CMV prophylaxis among liver transplant recipients have been incompletely defin

140 tors, and outcome of invasive candidiasis in liver transplant recipients have changed.

141 r fibrosis progression among black and white liver transplant recipients have not been investigated.

142 Centers with >30% of their liver transplant recipients hospitalized >/=30 days in t

143 r, other studies showed a high prevalence in liver transplant recipients immediately after, or some t

144 Mycobacterium llatzerense that occurred in a liver transplant recipient in the midwestern United Stat

145 is a significant disparity in MELD scores in liver transplant recipients in small vs large OPOs; fewe

146 sitive and recipient CMV-seronegative (D+R-) liver transplant recipients in the current era are incom

147 hort study analyzed all adult deceased donor liver transplant recipients in the Scientific Registry o

148 al of all adult, first-time, deceased-donor, liver transplant recipients in the United States since t

149 udy, HIV-positive to HIV-positive kidney and liver transplant recipients in the USA were examined for

150 titis C virus (HCV)-specific CD8+ T cells in liver transplant recipients in whom the allograft is HLA

151 Few data exist in liver transplant recipients, in whom exercise should be

152 fective for the prevention of CMV disease in liver transplant recipients, including high-risk patient

153 romboembolic events across a wide variety of liver transplant recipients, including those at low risk

154 Liver transplant recipients infected with hepatitis C vi

155 In hepatitis C virus (HCV)-positive liver transplant recipients, infection of the allograft

156 ormed donor-specific HLA antibodies (DSA) in liver transplant recipients is increasingly recognized;

157 therapy for cytomegalovirus (CMV) disease in liver transplant recipients is not known.

158 hown to enhance immunoregulatory profiles in liver transplant recipients (LTR), mTOR-I therapy might

159 nfections remain a significant problem among liver transplant recipients (LTRs).

160 of early readmissions and its predictors in liver transplant recipients (LTRs).

161 in eight HTRs (ages 57 +/- 6 years) and six liver-transplant recipients (LTRs) (ages 52 +/- 2 years)

162 ansplant recipients, but fewer data exist on liver-transplant recipients (LTRs).

163 Operationally tolerant pediatric liver transplant recipients maintain generally stable al

164 from the case notes of 181 consecutive adult liver transplant recipients (median follow-up 54 months)

165 A total of 592 liver transplant recipients met the inclusion criteria;

166 In an open-label, multicenter study, stable liver transplant recipients (n=69) were converted from t

167 9.0; 95% confidence interval, 1.8-45.8) and liver transplant recipients (odds ratio, 12.1; 95% confi

168 cipients between 2006-2017, we compared 2048 liver transplant recipients of steatotic livers to 69 39

169 ents between 2006 and 2017, we compared 2048 liver transplant recipients of steatotic livers with 69

170 port the clinical course and management of a liver transplant recipient on hemodialysis, who presente

171 s little is known about the opinion of Dutch liver transplant recipients on anonymity of organ donati

172 lood mononuclear cells from a group of eight liver transplant recipients, one of whom had stopped all

173 Among liver transplant recipients, only two of 20 patients rec

174 Three groups of stable liver transplant recipients: operationally tolerant (TOL

175 Records of all adult liver transplant recipients over 4 years were reviewed (

176 Sixty-four percent of liver transplant recipients overall experience a decreas

177 Among D+R- liver transplant recipients, PET was associated with the

178 gh macrosteatosis grafts in the obese modern liver transplant recipient population.

179 ained suppression of HCV replication in this liver transplant recipient provides great promise for th

180 In the United States, 5% of adult liver transplant recipients receive a graft donation aft

181 an important one because the benefits to the liver transplant recipient receiving a kidney transplant

182 clearance of disseminated ADV infection in a liver transplant recipient receiving CDV infusions.

183 98 to November 2001, 81 pediatric orthotopic liver transplant recipients receiving 89 liver grafts we

184 eceptor 1 gene, Angiotensinogen gene) in 233 liver transplant recipients receiving Cyclosporine (CsA)

185 hronic rejection does not occur in pediatric liver transplant recipients receiving tacrolimus-based i

186 Among D+R- liver transplant recipients receiving valganciclovir as

187 galactomannan (GM) and beta-D-glucan (BG) in liver transplant recipients remains uncertain.

188 cii pneumonia (PCP) occurred among renal and liver transplant recipients (RTR and LTR) in the largest

189 file of biomarkers that predict tolerance in liver transplant recipients (see the related article beg

190 nt randomized phase III study of 719 de novo liver transplant recipients showed that early everolimus

191 Liver transplant recipients suffer many postoperative co

192 present data from a retrospective review in liver-transplant recipients suffering from HCV recurrenc

193 pression might improve long-term outcomes in liver transplant recipients than IR-T-based immunosuppre

194 In liver transplant recipients the majority of circulating

195 In HCV-positive liver transplant recipients, the liver graft is colonize

196 lobe living-donor hepatectomies for 95 adult liver-transplant recipients, the largest single institut

197 ence of viral infections and malignancies in liver transplant recipients, this gene set provides an i

198 ized multicenter open-label trial in de novo liver transplant recipients to assess the feasibility an

199 We retrospectively studied kidney and kidney/liver transplant recipients to estimate their POAF incid

200 al assays before and after SRL conversion in liver transplant recipients to test for enhanced markers

201 analysis in operationally tolerant pediatric liver transplant recipients (TOL), those undergoing pros

202 operational tolerance in pediatric and adult liver transplant recipients, transcriptional profiles we

203 Despite this, the long-term outcomes of HCV+ liver transplant recipients transplanted from HCV+ donor

204 Our aim is to evaluate long-term outcomes in liver transplant recipients transplanted with HCV antibo

205 For 326 liver transplant recipients, transplanted between 2000 a

206 tcome of 265 consecutive chronic hepatitis B liver transplant recipients treated with entecavir monot

207 he same eligibility criteria consisted of 50 liver transplant recipients treated with our standard Ta

208 ce of 30% to 37% in kidney and 44% to 45% in liver transplant recipients treated with tacrolimus.

209 rs for new-onset diabetes mellitus (NODM) in liver transplant recipients using the Organ Procurement

210 f virus by culture in patients only when the liver transplant recipient was CMV immune before transpl

211 registry and Medicare claims data for 12,803 liver transplant recipients was developed to capture inf

212 Hepatocellular carcinoma incidence among liver transplant recipients was elevated overall (SIR 3.

213 e tolerability of daily interferon dosing in liver transplant recipients was evaluated and effects on

214 A retrospective analysis of 396 liver transplant recipients was performed at the Medical

215 le-center study of 137 consecutive pediatric liver transplant recipients was to examine the effect of

216 In orthotopic liver transplant recipients we found a 26% incidence of

217 is single-center study of 88 consecutive DCD liver transplant recipients were (1) to compare renal ou

218 Forty-four thousand seven hundred fifty-six liver transplant recipients were analyzed.

219 n studies reporting outcomes for DCD and DBD liver transplant recipients were considered.

220 Cadaveric liver transplant recipients were enrolled from January 2

221 Thirty consecutive liver transplant recipients were enrolled in this prospe

222 IV-positive to HIV-positive kidney and eight liver transplant recipients were followed from March, 20

223 udy, HIV-positive to HIV-positive kidney and liver transplant recipients were followed in three hospi

224 Eighty-eight liver transplant recipients were included in this study.

225 kidney transplant recipients and 20 cases in liver transplant recipients were included.

226 Liver transplant recipients were more likely to have dis

227 Adult liver transplant recipients were randomized on the day o

228 In this clinical trial, 129 liver transplant recipients were randomized to be monito

229 A total of 2050 liver transplant recipients were studied, of these 960 (

230 udy, serial blood samples from 689 kidney or liver transplant recipients were tested for CMV DNA by q

231 Fifty-seven liver-transplant recipients were included, 29 naive (gro

232 viral growth during infection of HCMV-naive liver transplant recipients, whereas lower efficacy leve

233 thern California to create a database of 598 liver transplant recipients, which incorporates diagnost

234 scribe the first case in the literature of a liver transplant recipient who developed an infrarenal a

235 d by B. multivorans occurring in a pediatric liver transplant recipient who does not have cystic fibr

236 ssociated visceral angioedema occurring in a liver transplant recipient who presented with acute-onse

237 We describe the case of a liver transplant recipient who presented with an acute f

238 single-center retrospective analysis of 207 liver transplant recipients who achieved MELD score of 4

239 but is similar to what would be expected in liver transplant recipients who did not have ESRD.

240 ubjects consisted of 27 hepatitis C-infected liver transplant recipients who had liver biopsy specime

241 We included consecutive adult liver transplant recipients who had their surgery betwee

242 disease is an important clinical problem in liver transplant recipients who receive antiviral prophy

243 risk factors for CMV disease in a cohort of liver transplant recipients who received antiviral proph

244 the first posttransplant year in a cohort of liver transplant recipients who received antiviral proph

245 transplantation in cohorts of high-risk D+R- liver transplant recipients who received either PET (n =

246 ologic injury due to histoincompatibility in liver transplant recipients who received sequential kidn

247 initiation of isoniazid chemoprophylaxis in liver transplant recipients who test positive on the tub

248 In conclusion, pediatric liver transplant recipients who undergo transfer to the

249 OS did not differ between liver transplant recipients who were not pretreated or p

250 Pediatric liver transplant recipients who were successfully withdr

251 and quantified the circulating ApoL1 in two liver transplant recipients whose native APOL1 genotype

252 psy-proven regression of liver fibrosis in a liver transplant recipient with cirrhosis after chronic

253 We describe a 57-year-old liver transplant recipient with decompensated graft cirr

254 inimal transient side effects in a pediatric liver transplant recipient with disseminated adenoviral

255 of an interferon-free, all oral regimen in a liver transplant recipient with severe recurrent HCV.

256 er-related death, or retransplantation among liver transplant recipients with a CC genotype donor.

257 Between 1996 and 2002, 33 liver transplant recipients with a clinical suspicion of

258 We reviewed all records of adult kidney and liver transplant recipients with a GI tract biopsy and p

259 are leading causes of long-term mortality in liver transplant recipients with ALD or NAFLD.

260 in the tubulointerstitium of kidneys from 15 liver transplant recipients with biopsy-confirmed chroni

261 stochemical analyses of kidney biopsies from liver transplant recipients with chronic CsA nephrotoxic

262 C57BL/6 J wild type and Nox2-/- mice, and in liver transplant recipients with chronic CsA nephrotoxic

263 g three times daily) in 303 CMV-seronegative liver transplant recipients with CMV-seropositive donors

264 of CMV disease in high-risk CMV-seronegative liver transplant recipients with CMV-seropositive donors

265 Cytomegalovirus (CMV)-seronegative liver transplant recipients with CMV-seropositive donors

266 large report of DC as a viable strategy for liver transplant recipients with coagulopathy or hemodyn

267 ciated conditions that are being provided to liver transplant recipients with diabetes have not yet b

268 In liver transplant recipients with Epstein-Barr virus (EBV

269 th a short course (in hospital only) HBIG in liver transplant recipients with HBV DNA less than 100 I

270 ransplantation survival of adult, first-time liver transplant recipients with HCC (n = 9135) or witho

271 PGB in 138 consecutive adult, deceased donor liver transplant recipients with HCC.

272 ecipients (1995-2013), we selected all adult liver transplant recipients with HCV, and cross-sectiona

273 ecember 19, 2011 and January 25, 2013, seven liver transplant recipients with hepatitis C received be

274 A retrospective review of adult liver transplant recipients with hepatitis C receiving b

275 ucted a multicenter case-control study of 52 liver transplant recipients with hepatitis C to assess t

276 Thirty-five consecutive liver transplant recipients with invasive candidiasis we

277 In this cohort of liver transplant recipients with long-term follow-up, no

278 nt trend toward the use of elderly donors in liver transplant recipients with low model of end-stage

279 tric bypass can be successfully performed in liver transplant recipients with morbid obesity and may

280 Liver transplant recipients with NASH have a higher risk

281 novo post-transplant type 2 diabetes (DM) in liver transplant recipients with NASH.

282 ed a retrospective cohort study of 749 adult liver transplant recipients with pre- and posttransplant

283 Liver transplant recipients with recurrent HCV (elevated

284 osuppression regimen in hepatitis C-positive liver transplant recipients with renal dysfunction, and

285 lowing liver transplantation alone or SLK in liver transplant recipients with renal dysfunction.

286 to assess the safety and efficacy of SRL in liver transplant recipients with renal dysfunction.

287 transplantation (CLKT) improves survival for liver transplant recipients with renal dysfunction; howe

288 transplantation (CLKT) improves survival for liver transplant recipients with renal dysfunction; howe

289 ntiviral prophylaxis in 205 CMV-seronegative liver transplant recipients with seropositive donors age

290 l prophylaxis for high-risk CMV-seronegative liver transplant recipients with seropositive donors, hi

291 Among CMV-seronegative liver transplant recipients with seropositive donors, th

292 It is important to avoid PEG therapy in liver transplant recipients with specific clinical, bioc

293 Liver transplant recipients with type 1 or CAD have appr

294 Liver-transplant recipients with CMV infection, includin

295 ution that must be taken when treating HCV-R liver-transplant recipients with combination pegylated a

296 We enrolled 34 liver-transplant recipients with no fibrosis or mild fib

297 h rate of sustained virologic response among liver-transplant recipients with recurrent HCV genotype

298 merase inhibitor dasabuvir, and ribavirin in liver-transplant recipients with recurrent HCV genotype

299 ong-term treatment with ribavirin is safe in liver transplant recipients, without achieving HEV susta

300 However, most liver transplant recipients would like to receive some g